Department of Neurosurgery, King's College Hospital, London, U.K.
Department of Neurosurgery, St George's Hospital, London, U.K.
Anticancer Res. 2020 Jun;40(6):3081-3089. doi: 10.21873/anticanres.14289.
Grade I meningiomas are generally benign and non-invasive whereas Grade II (atypical) and Grade III (malignant) meningiomas tend to be invasive with a high risk of recurrence. SPARC, secreted protein, acidic and rich in cysteine, is a multifunctional glycoprotein which has been proposed to be a potential diagnostic marker of invasive meningiomas. There has been increased reporting of atypical meningiomas since the current World Health Organization (WHO) included brain invasion as a grading criterion for classification of these particular meningiomas.
The aim of this study was to re-evaluate any correlation between immunohistochemical expression of SPARC in 34 meningiomas of various grades using the current classification (2016). We had previously classified these cases using the 2002 WHO criteria.
There is no correlation between expression of SPARC and invasion in different grades of meningioma.
SPARC does not appear to be a good predictor of invasion in meningiomas.
I 级脑膜瘤通常为良性且非侵袭性的，而 II 级（非典型性）和 III 级（恶性）脑膜瘤往往具有侵袭性，且复发风险较高。富含半胱氨酸的酸性分泌糖蛋白（SPARC）是一种多功能糖蛋白，已被提议作为侵袭性脑膜瘤的潜在诊断标志物。自现行的世界卫生组织（WHO）将脑侵袭纳入这些特定脑膜瘤分类的分级标准以来，非典型脑膜瘤的报告有所增加。
本研究的目的是使用现行（2016 年）分类重新评估 34 例不同分级脑膜瘤中 SPARC 的免疫组织化学表达之间的任何相关性。我们之前使用 2002 年 WHO 标准对这些病例进行了分类。
SPARC 的表达与脑膜瘤不同分级的侵袭性之间无相关性。
SPARC 似乎不是脑膜瘤侵袭的良好预测因子。
